Skip to main content

Table 3 KPIs for the Henan STEMI registry

From: Rationale and design of the Henan ST elevation myocardial infarction (STEMI) registry: a regional STEMI project in predominantly rural central China

Primary performance measures
During hospitalization
 Proportion of patients receiving aspirin at arrival
 Proportion of patients receiving P2Y12 inhibitor at arrival
 Proportion of patients arrival by emergency ambulance
 Proportion of patients receiving early reperfusion therapy
 Proportion of patients receiving fibrinolytic therapy within 30 min of first medical contact among those receiving this treatment
 Proportion of patients receiving primary PCI within 90 min of first medical contact among those receiving this treatment
 Proportion of patients with evaluation of left ventricular function by echocardiography
At discharge
 Proportion of patients receiving aspirin at discharge
 Proportion of patients receiving P2Y12 inhibitor at discharge
 Proportion of patients receiving statin at discharge
 Proportion of patients with indications receiving a β-blocker at discharge
 Proportion of patients with indications receiving an ACEI or ARB at discharge
 In-hospital all-cause mortality
 In-hospital death or treatment withdrawal
 In-hospital MACCE (death, congestive heart failure, reinfarction and ischemic stroke)
Follow-up
 Proportion of patients receiving 1-month on-time follow-up
 Proportion of patients receiving 6-month on-time follow-up
 Proportion of patients receiving 1-year on-time follow-up
Secondary performance measures
 Proportion of patients receiving first ECG within 10 min of first medical contact
 Proportion of delayed primary PCI (Time from first medical contact to primary PCI > 90 min)
 Proportion of patients receiving anticoagulants at arrival (within 24 h)
 Proportion of patients receiving determination of blood LDL level
 Proportion of patients receiving P2Y12 inhibitor at discharge among those receiving reperfusion
 Proportion of patients receiving P2Y12 inhibitor at discharge among those without receiving reperfusion
 Proportion of patients receiving aspirin and P2Y12 inhibitor at discharge
  1. ACEI Angiotensin-converting enzyme inhibitor, ARB Angiotensin receptor blocker, ECG Electrocardiograph, LDL Low density lipoprotein, MACCE Main adverse cardiovascular and cerebrovascular events, PCI Percutaneous coronary intervention